about
Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.Prevention and management of hepatitis B virus reactivation in cancer patients.Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study.Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatmentAssociation Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016.Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B.Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study.Risk of gastric cancer development after eradication of Helicobacter pylori.Effects of Helicobacter PYLORI Treatment on Incidence of Gastric Cancer in Older Individuals.Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance.Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancerLong-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidenceSystematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel.Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug usersPrevention of post-sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trialRisks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysisResponse to letter to the editor by Moayyedi et alCorrelation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infectionStatins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients
P50
Q38383062-2ADF51A0-243B-4ADC-ADDD-92E7D131FD29Q38688782-5D992F73-7865-419C-928A-9BE59CA73E62Q39099698-AE7C1A0A-A044-4B6A-B18B-0677436A86CEQ39217774-494504A0-31B0-4EA4-8BBD-F487E6116A5DQ40096029-94447EA9-E427-4930-BB7D-A98584118BDFQ40341578-D8628DDF-3D6C-4233-A7DB-90B5B815B792Q40404314-757CB0D6-0F5F-40F4-8E9E-767AF2D8F9E5Q40436747-BC40C1EF-70F1-4484-BA84-384B87AA66D2Q40575142-A4580AF3-6DE0-4FA9-94D7-5BBB6B91D516Q41209771-5EE2FC7F-DAB9-42C9-B7D2-EB0BB8EFF8CDQ41249783-7B8EA3FF-7FA7-430B-B4DB-72C77356665CQ41471144-B6FD5CB0-2135-49F2-8DA6-866CC52EBA35Q41926033-0B713232-CBA5-41C0-9B10-941CE4B41B9AQ45326295-EB7873EB-14B2-40E3-8B6A-AE63553834BBQ47105522-585CE4FF-3BF8-464C-9C75-17D3F0F683FCQ47114292-EFBA80D3-A0E6-4801-AE75-303E4285EF13Q48339011-E81A9E71-616E-4BFA-A80D-E575712B6C4FQ51759180-0D851AC1-A02A-432B-8F92-0326ED8501BFQ54209299-26FCF02F-69CA-499A-B81A-32E8FBA1F7C1Q54254176-07B99045-E933-4376-BBD0-9C38E5854372Q54256777-F483E7FE-21F5-494E-939D-62989E07EF1CQ54325125-34B5313F-51B0-4ED6-B70A-652BA0AB7D4BQ55276444-750E5146-452F-4519-82C3-4978AD36D2DDQ57284277-814638B3-3F9E-4A4C-9E00-66C8819FF4D0Q64110359-2A3AB8E7-F1D0-4287-95A0-6A11D0A6BC76Q64915866-4DEF66B8-1FFE-413D-8EC7-A3300B6E990CQ88091627-352398BE-C84C-4C53-B8A7-D5CE9B15330AQ88552948-323A0174-7552-4EDA-BDDD-771BEFB58103Q90474463-22C86B25-7F1E-4650-9890-7FF8E5D41516Q91020956-FA5AD130-8D9D-4DA4-8FDC-E4E348D899F0Q91173090-952BA196-B5F3-44E2-8068-F8AFABDF016EQ91942147-C4B6906D-3CE1-4C5E-BD8E-CBD3A8569A95
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ka-Shing Cheung
@en
Ka-Shing Cheung
@nl
type
label
Ka-Shing Cheung
@en
Ka-Shing Cheung
@nl
prefLabel
Ka-Shing Cheung
@en
Ka-Shing Cheung
@nl
P31
P496
0000-0002-4838-378X